Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian P Kells

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 16, 2010
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNFAdrian P Kells, Jamie Eberling, Xiaomin Su, et al.
Frontiers in Neuroanatomy|March 28, 2014
Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: Implications for gene and drug therapyErnesto A Salegio, Hillary Streeter, Nikhil Dube, et al.
Annals of Neurology|February 26, 2019
Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's diseaseChadwick W Christine, Krystof S Bankiewicz, Amber D Van Laar, et al.
Human Gene Therapy|August 13, 2009
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeysXiaomin Su, Adrian P Kells, Eric J Huang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 1, 2020
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's diseaseR Mark Richardson, Krystof S Bankiewicz, Chadwick W Christine, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 21, 2025
Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's DiseaseAmber D Van Laar, Chadwick W Christine, Nicolás Phielipp, et al.
Molecular Therapy. Methods & Clinical Development|December 27, 2014
SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATEWaldy San Sebastian, Adrian P Kells, John Bringas, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 15, 2010
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's diseaseJosee Laganiere, Adrian P Kells, Jeffrey T Lai, et al.
Stereotactic and Functional Neurosurgery|April 16, 2011
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brainR Mark Richardson, Adrian P Kells, Alastair J Martin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 24, 2011
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's diseaseR Mark Richardson, Adrian P Kells, Kathryn H Rosenbluth, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 16, 2010
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNFAdrian P Kells, Jamie Eberling, Xiaomin Su, et al.
Frontiers in Neuroanatomy|March 28, 2014
Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: Implications for gene and drug therapyErnesto A Salegio, Hillary Streeter, Nikhil Dube, et al.
Annals of Neurology|February 26, 2019
Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's diseaseChadwick W Christine, Krystof S Bankiewicz, Amber D Van Laar, et al.
Human Gene Therapy|August 13, 2009
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeysXiaomin Su, Adrian P Kells, Eric J Huang, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 1, 2020
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's diseaseR Mark Richardson, Krystof S Bankiewicz, Chadwick W Christine, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 21, 2025
Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's DiseaseAmber D Van Laar, Chadwick W Christine, Nicolás Phielipp, et al.
Molecular Therapy. Methods & Clinical Development|December 27, 2014
SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATEWaldy San Sebastian, Adrian P Kells, John Bringas, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|December 15, 2010
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's diseaseJosee Laganiere, Adrian P Kells, Jeffrey T Lai, et al.
Stereotactic and Functional Neurosurgery|April 16, 2011
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brainR Mark Richardson, Adrian P Kells, Alastair J Martin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 24, 2011
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's diseaseR Mark Richardson, Adrian P Kells, Kathryn H Rosenbluth, et al.
Pageof 4